Home > Press Room > Events > Funding & Launching a University Biotech Spin-Off
  • Print
  • Send to email


Funding & Launching a University Biotech Spin-Off

Location: Rutgers Visitor Center, 100 Sutphen Rd, Piscataway Township, NJ 08854

Hosted in Partnership with:


Featuring Leaders of Biotech Academic Spin-Offs in New Jersey

Biotech leaders will tell their story and provide guidance and recommendations on launching and funding their academic biotech spin-off.  

Register now and join us at the Rutgers Visitor Center in Piscataway for networking and guidance from a panel of New Jersey's biotech leaders. 

The panelists will share their respective paths to success, including insights into their strategy and decisions faced along the way to their companies spinning out from a university.

Time & Location

Thursday, January 25, 2018
5:00 pm - 7:00 pm
Rutgers Visitor Center
100 Sutphen Rd, Piscataway Township, NJ 08854

Featured Speakers:


Dr. Benjamin Belinka, Actinobac Biomed, President & CEO 

Dr. Belinka obtained his Ph.D. in chemistry from State University of NY at Binghamton and has over 28 years of experience in the pharmaceutical and biotechnology industry as both a scientist and executive.  At Cytogen, Dr. Belinka, as Assistant Director of Preclinical Research & Chemistry, managed research laboratories and supported the advancement of the company’s diagnostic and bone pain agents through preclinical and clinical development. Joining VectraMed, Inc. in 1998 as its Director of Chemistry and later as Vice President, Dr. Belinka was responsible for designing the company’s proprietary drug delivery technology, organizing and setting up its research facilities, and negotiating cooperative research programs with major pharmaceutical organizations such as (Elan, Pfizer, Ethicon, & Aventis) providing over $7 million in revenue. Dr. Belinka has more than a dozen scientific publications and abstracts and 15 patents.

Actinobac Biomed is a Rutgers University spin-off.


Nick Crider, Visikol, COO & Co-Founder  

Viskiol is a biotech company that "allows scientists to visualize tissues in 3-D as opposed to the traditional 2-D slices."  Nick is responsible for both overall strategic and day-to-day operations of the company. Nick oversees the regulatory and legal concerns for Visikol..

Visikol is a Rutgers University spin-off.



Vincent Smeraglia, Executive Director of Strategic Alliances, Rutgers University

Vince is the Executive Director of Strategic Alliances, developing biomedical Rutgers collaborative relationships with universities, foundations and corporate partners. Previously, he was the Executive Director of the Rutgers Office of Technology Commercialization, overseeing patenting and licensing of Rutgers inventions. He was also the Executive Director of the UMDNJ Office of Technology Transfer & Business Development before UMDNJ and Rutgers merged.

About CCIT: NJEDA's CCIT Life Sciences Incubator is located in a 50-acre research park owned by the NJ Economic Development Authority. CCIT is almost 50,000 s.f., with 27 wet labs and access to offices, conference rooms, biotech training events, mentoring and a great biotech ecosystem.  The larger park itself is home to Chromocell, Allergan, Merial and Orthobond.  

Rutgers Innovation Alley at CCIT:  CCIT has partnered with Rutgers University to offer discounted space for academic spin-off companies.  For eligible academic spin-offs, office space is available for as little as $333/month.  Discounted lab space for academic spin-off companies is available at similar savings. 

For more information on CCIT, contact Lenzie Harcum at lharcum@njeda.com.


Company Affiliation:

Email Address: